BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 11194088)

  • 1. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
    Crowell EB; Jubelirer SJ
    W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of breast cancer in high-risk women.
    Kardinal CG; Veith R
    J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
    Jubelirer SJ; Crowell EB
    W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Breast Cancer Prevention Trial (BCPT) in West Virginia.
    Jubelirer SJ; Crowell EB
    W V Med J; 1992 Sep; 88(9):399-401. PubMed ID: 1462531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN
    Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
    Vogel VG
    J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer prevention trial.
    Elias EG; Brown SD; Buda BS; Honts SL
    Md Med J; 1994 Mar; 43(3):249-52. PubMed ID: 8201852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First do no harm: extending the debate on the provision of preventive tamoxifen.
    Will BP; Nobrega KM; Berthelot JM; Flanagan W; Wolfson MC; Logan DM; Evans WK
    Br J Cancer; 2001 Nov; 85(9):1280-8. PubMed ID: 11720461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM; Christo DK; Lai H; Helzlsouer K
    Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.